12:00 AM
Feb 06, 2012
 |  BioCentury  |  Product Development

Specifying stroke

Thrombolytic Science targeting ischemic stroke with combination product TS01

Thrombolytic Science International LLC is developing a combination product to target only the clots that lead to stroke, which it expects will significantly reduce bleeding and potentially double the treatment window compared with the only drug approved for the indication.

The company, which was founded in 2006 but emerged from stealth mode in January, is developing a mutated version of pro-urokinase. Urokinase is a serine protease that activates plasminogen to start the proteolysis cascade, leading to clot thrombolysis.

Because pro-urokinase is unstable in plasma and is vulnerable to non-specific activation into urokinase in the plasma, therapeutic doses of the protein caused unacceptable levels of bleeding in patients in clinical trials in the '80s and '90s, according to Alexis Wallace, president, CEO and co-founder of Thrombolytic Science.

The company is thus developing TS01, combining the mutant pro-urokinase with a plasma complement 1 (C1) esterase inhibitor, which Wallace said augments the mutant's lytic ability while helping...

Read the full 770 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >